Skip to main content

Table 6 The association between baseline serum alkaline phosphatase (ALP) and new-onset diabetes, with further adjustment for AST, ALT and GGT

From: Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults

ALP, IU/L

N

No. of events (%)

Crude model

Adjusted model*

OR (95% CI)

P value†

OR (95% CI)

P value†

Continuous, per SD increment

14,393

1549 (10.8)

1.07 (1.02,1.13)

0.007

1.06 (1.00,1.13)

0.045

Quartiles

 Q1 (< 79)

3486

343 (9.8)

1.00 (ref.)

 

1.00 (ref.)

 

 Q2 (79- < 96)

3623

381 (10.5)

1.08 (0.92,1.26)

0.346

1.08 (0.92,1.28)

0.327

 Q3 (96- < 116)

3577

390 (10.9)

1.12 (0.96,1.31)

0.143

1.13 (0.96,1.33)

0.148

 Q4 (≥ 116)

3707

435 (11.7)

1.22 (1.05,1.42)

0.010

1.23 (1.03,1.46)

0.020

P for trend

  

0.009

 

0.019

 
  1. ALP serum alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, eGFR estimated glomerular filtration rate, GGT gamma glutamyl transpeptidase, OR odds ratio, SD standard deviations, SBP systolic blood pressure
  2. *Adjusted for age, sex, study center, treatment group, body mass index (BMI), smoking, alcohol drinking, family history of diabetes, SBP, fasting glucose (FG), total cholesterol (TC), triglycerides (TG), eGFR, folate, total homocysteine and the use of antihypertensive drugs, AST, ALT, GGT at baseline, as well as time-averaged SBP during the treatment period
  3. †In comparison with the first quartile